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Abstract
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Platelet-activating factor (PAF) is a potent phospholipid mediator that exerts various
pathophysiological effects by interacting with a G protein-coupled receptor. PAF has been reported
to increase the permeability of the blood-brain barrier (BBB) via incompletely characterized
mechanisms. We investigated the effect of PAF on rat brain microvascular endothelial cells
(RBMVEC), a critical component of the BBB. PAF produced a dose-dependent increase in
cytosolic Ca2+ concentration; the effect was prevented by the PAF receptor antagonist, WEB2086.
The effect of PAF on cytosolic Ca2+ was abolished in Ca2+-free saline or in the presence of L-type
voltage-gated Ca2+ channel inhibitor, nifedipine, indicating that Ca2+ influx is critical for PAFinduced increase in cytosolic Ca2+. PAF produced RBMVEC depolarization; the effect was
inhibited by WEB2086. In cells loaded with DAF-FM, a nitric oxide (NO)-sensitive fluorescent
dye, PAF increased the NO level; the effect was prevented by WEB2086, nifedipine or by LNAME, an inhibitor of NO synthase. Immunocytochemistry studies indicate that PAF reduced the
immunostaining of ZO-1, a tight junction-associated protein, increased F-actin fibers, and
produced intercellular gaps. PAF produced a decrease in RBMVEC monolayer electrical
resistance assessed with Electric Cell-Substrate Impedance Sensing (ECIS), indicative of a
disruption of endothelial barrier function. In vivo studies indicate that PAF increased the BBB
permeability, assessed with sodium fluorescein and Evans Blue methods, via PAF receptordependent mechanisms, consequent to Ca2+ influx and increased NO levels. Our studies reveal
that PAF alters the BBB permeability by multiple mechanisms, which may be relevant for central
nervous system (CNS) inflammatory disorders.
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Introduction

Author Manuscript

Platelet-activating factor (PAF) is a bioactive phospholipid messenger, originally reported to
produce platelet aggregation after being released from IgE-sensitized basophils (Benveniste
et al., 1972). In addition to platelet activation, PAF has been ascribed to other physiological
and pathophysiological functions (Prescott et al., 2000, Liu et al., 2016). PAF is a potent
inflammatory factor, involved in pathogenesis of several diseases such as anaphylaxis,
asthma, rheumatoid arthritis, atherosclerosis, glomerulosclerosis, and diabetes (Hilliquin et
al., 1995, Prescott et al., 2000, Tsoupras et al., 2009, Liu et al., 2016). PAF also induces
smooth muscle contraction, and increases vascular permeability (Kornecki and Ehrlich,
1988, Lacerda-Queiroz et al., 2012, Vadas et al., 2013, Jeewandara et al., 2015).
PAF synthesis occurs via two pathways

de novo, and by the cytosolic phospholipase A2-dependent remodeling pathway, with the
latter being predominant (Liu et al., 2016). Similarly to the eicosanoids, PAF is not stored
preformed, but rapidly synthesized intracellularly in response to cell-specific stimuli
(Prescott et al., 2000). Synthesis and release of PAF occur in a variety of cells,
predominantly in endothelial cells and leukocytes (Aliberti et al., 1999, Mariano et al.,
2003). The synthesis, distribution and degradation of PAF are tightly controlled, contributing
to brief and selective responses (Prescott et al., 2000).

Author Manuscript

PAF exerts its effects by interaction with a G protein-coupled receptor, namely PAF receptor
(Alexander et al., 2015). PAF receptor, the first cloned receptor for lipids, is expressed in a
variety of cell types (Honda et al., 1991, Bito et al., 1994, Ihida et al., 1999), including brain
microvascular cells (Predescu et al., 1996). Activation of the PAF receptor promotes inositol
trisphosphate (IP3) formation via phospholipase C (PLC) stimulation; it also stimulates
protein kinases, such as protein kinase C and tyrosine kinase (Barzaghi et al., 1989, Shukla,
1992). In addition, PAF was shown to produce Ca2+ influx in cell lines such as NG108-15,
mouse neuroblastoma-rat glioma cells, and PC12, rat pheochromocytoma cells (Kornecki
and Ehrlich, 1988).
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In the central nervous system (CNS), PAF was involved in the inflammatory response,
pathogenesis of meningitis, ischemia-reperfusion injury, stroke, multiple sclerosis,
Alzheimer's and Parkinson's diseases, or HIV-associated neurocognitive disorders
(Feuerstein, 1996, Maclennan et al., 1996, Liu et al., 2016, Reiner et al., 2016). PAF has
been reported to produce a transient increase in blood-brain barrier (BBB) permeability
(Fang et al., 2011, Fang et al., 2014), however the effects of PAF on endothelial cells of the
BBB remain incompletely characterized. The current study investigated the effects elicited
by PAF on rat brain microvascular endothelial cells, an experimental model of BBB, on
cytosolic Ca2+ concentration, membrane potential, nitric oxide (NO) level and electrical
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resistance. In addition, in vivo studies examined the contribution of the pathways identified
for PAF in vitro on the rat BBB permeability.

Experimental Procedures
Ethical approval
Animal protocols were approved by the Institutional Animal Care and Use Committee from
each institution.
Chemicals and reagents

Author Manuscript

PAF (C-16 PAF) and WEB2086 were from Tocris Biosciences (Bristol, UK). Fura-2AM,
DAF-FM, DiBAC4(3), and ActinRed555 were from Molecular Probes (ThermoFisher
Scientific, Waltham, MA). Other reagents were from Sigma-Aldrich (St. Louis, MO) unless
otherwise mentioned.
Cell Culture
Rat brain microvascular endothelial cells (RBMVEC), purchased from Cell Applications,
Inc (San Diego, CA) were cultured as previously described (Altmann et al., 2015, Brailoiu et
al., 2017). Cells were grown in endothelial basal medium enriched with endothelial growth
supplement, in T75 flasks coated with attachment factor (Cell Applications, Inc). For
immunocytochemistry studies, cells were plated on 12 mm diameter glass coverslips. For
live imaging studies, cells were grown on 25 mm diameter glass coverslips coated with
human fibronectin (Discovery Labware, Bedford, MA). For impedance measurements, cells
were grown on 8W10E+ arrays (Applied BioPhysics, Inc., Troy, NY) coated with
fibronectin.
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Cytosolic Ca2+ measurement
Cytosolic Ca2+ concentration, [Ca2+]i, was assessed in RBMVEC loaded with Fura-2 AM
(Molecular Probes, ThermoFisher Scientific, Waltham, MA), as previously described
(Altmann et al., 2015, Brailoiu et al., 2016, Brailoiu et al., 2017). Cells on coverslips were
incubated with Fura-2 AM (5 μM, 1 hour, room temperature) in Hanks' Balanced Salt
Solution (HBSS). Coverslips, after washing with dye-free HBSS, were mounted on the stage
of a Nikon Eclipse TiE microscope (Nikon Inc., Melville, NY), in an open bath chamber.
Fura-2 AM fluorescence (emission 510 nm), following alternate excitation at 340 and 380
nm, was recorded using a Photometrics CoolSnap HQ2 CCD camera (Photometrics, Tucson,
AZ) and NIS-Elements AR software (Nikon). The ratio of the fluorescence signals (340/380
nm) was converted to Ca2+ concentrations (Grynkiewicz et al., 1985).

Author Manuscript

Measurement of membrane potential
Changes in RBMVEC membrane potential were assessed using a voltage-sensitive dye, bis(1,3-dibutylbarbituric acid)-trimethine-oxonol, DiBAC4(3) (Molecular Probes), as reported
(Brauner et al., 1984, Altmann et al., 2015). RBMVEC were incubated in DiBAC4(3) (0.5
μM in HBSS, 30 min) and the fluorescence (excitation/emission 480 nm/540 nm) monitored.
Membrane depolarization produces an increase in fluorescence intensity consequent to
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accumulation of the dye into the cytosol, (Brauner et al., 1984). Calibration of DiBAC4(3)
fluorescence was performed as previously reported (Altmann et al., 2015).
NO measurement
Intracellular NO was measured in RBMVEC loaded with DAF-FM [(4-amino-5methylamino-2′,7′-difluoro-fluorescein) diacetate] (Molecular Probes) as described
(Kojima et al., 1998, Altmann et al., 2015). RBMVEC were incubated in DAF-FM (0.5 μM
in HBSS, 45 min, room temperature) (Leikert et al., 2001) and the DAF-FM fluorescence
(excitation/emission 480 nm/ 540 nm was monitored.
Immunocytochemistry
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Immunocytochemistry studies were performed as described earlier (Brailoiu et al, 2011,
Brailoiu et al, 2017). RBMVEC grown on 12 mm diameter glass coverslips, were treated for
10 min with PAF (1 μM), WEB2086 (5 μM), L-NAME (100 μM), nifedipine (1 μM). in
other experiments, cells were treated with WEB2086, L-NAME or nifedipine for 15 min,
followed by PAF for 10 min; untreated cells served as control. After rinsing with phosphate
buffer saline (PBS), cells were fixed in 4% paraformaldehyde. Cell fixation was followed by
additional rinsing with PBS and PBS with 0.5% Triton X for 5 min, and incubation with
normal goat serum. Cells were then incubated with primary antibody ZO-1 (rabbit IgG,
Molecular Probes) overnight at 4°C, followed by incubation with secondary antibody (goat
anti-rabbit, conjugated to Alexa 488, 2 hours, room temperature). Cells were washed in PBS
and incubated with ActinRed 555 (30 min, room temperature). After washing in PBS, cells
were mounted with DAPI Fluoromount G (SouthernBiotech, Birmingham, AL), sealed, and
examined under a Leica DMI6000B fluorescence microscope.
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Impedance Measurements
Impedance measurements were carried out via electric cell-substrate impedance sensing
(ECIS) method, using a Zθ controller, an 16W array holder station and 8W10E+ arrays,
similarly with previous reports (Stolwijk et al, 2015, Stolwijk et al, 2016). RBMVEC were
cultured at a density of 100,000 cells/cm2 on 8W10E+ arrays treated with L-cysteine (10
mM, 200 μl/well, 20 min, room temperature) and coated with fibronectin (50μg/ml, 200 μl/
well, 30 min, 37°C). Cells were grown on arrays for 48 h in an incubator (37°C, 5% CO2,
humidified atmosphere) before drug treatment. To assess the change in paracellular currents
in response to agonists (PAF and histamine), the resistance part of impedance, was
normalized to the value before the addition of the agonist and plotted as function of time.
MTT assay

Author Manuscript

We assessed the cell viability using a colorimetric assay with methylthiazolyldiphenyltetrazolium bromide (MTT). This assay is based on the conversion of the water-soluble
tetrazolium salt (yellowish) by mitochondrial dehydrogenase of living cells to waterinsoluble formazan (dark-blue). RBMVEC were cultured in 96-well plates at a density of
10,000 cells/well. After 48 hours in culture, cells were treated with PAF (0.1- 5 μM) for one
hour. Cells were treated with MTT (10 μl/well) and incubated at 37°C for 3 hours. The
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medium containing MTT was removed and DMSO (50 μl/well) added. After gently mixing
for 5 min, the absorbance at 570 nm was read using a Synergy plate reader.
Permeability assay with sodium fluorescein

Author Manuscript

BBB permeability was assessed by measuring the sodium fluorescein content in the rat
brain, similarly with previous reports (Lenzser et al., 2007). The drugs tested or saline
(control) were administered i.v. in the tail vein 30 min after systemic injection of sodium
fluorescein (2%, 4 mL/kg). One hour after drug administration, the rats were anesthetized
and transcardially perfused with ice-cold PBS. The brain was removed, rinsed, weighted and
homogenized in PBS. The homogenate was treated with trichloroacetic acid (80%), then
centrifuged (20 mins, 10,000g). The supernatant was diluted with 5 M NaOH, and its
fluorescence was determined (excitation/emission- 440 nm/525 nm) using a microplate
reader. The concentration of sodium fluorescein in the brain was quantified and expressed
per gram of tissue.
Evans Blue extravasation method
BBB disruption was assessed quantitatively by measuring Evans Blue extravasation as
previously reported (Uyama et al., 1988, Radu and Chernoff, 2013). Evans blue 2% in PBS
(4 mg/Kg) was injected i.v. via tail vein, 30 min before the administration of drugs tested.
One hour later, rats were anesthetized with ketamine (100 mg/kg) and perfused
transcardially with PBS. The brain was dissected, weighed and homogenized in PBS. The
homogenate was treated with trichloroacetic acid (80%,), incubated at 4 °C, 1 h and
centrifuged (20 min, 10,000 g). The supernatant's absorbance at 610 nm was determined
using a plate reader. Brain Evans Blue concentration was quantified from a linear standard
curve plotted from known amounts of Evans Blue dye.
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Statistical analysis
Data were expressed as mean ± standard error of mean. One-way ANOVA followed by
Bonferonni and Tukey tests was used to evaluate significant differences between groups; P <
0.05 was considered statistically significant.

Results
PAF increases cytosolic Ca2+ concentration, [Ca2+]i , in RBMVEC

Author Manuscript

The cytosolic Ca2+ concentration, [Ca2+]i, before and after treatment with PAF was assessed
in Fura 2-AM-loaded RBMVEC cells. PAF (1 μM) increased the RBMVEC fluorescence
ratio F340/F380 (Fig. 1A). The increase in fluorescence was converted to Ca2+ concentration
(Grynkiewicz et al., 1985). PAF produced a fast and transient increase in [Ca2+]i, that was
inhibited by the PAF receptor antagonist, WEB2086 (5 μM). Cells were pretreated with
WEB2086 for 15 min before PAF treatment. Examples of averaged Ca2+ responses induced
by PAF, and by PAF in the presence of WEB2086 are shown in Fig 1B. The comparison of
the amplitude of Ca2+ responses produced by different concentrations of PAF (0.1-5 μM) is
shown in Fig. 1C. PAF (0.1 μM, 0.5 μM, 1 μM and 5 μM) produced an increase in [Ca2+]i by
73 ± 1.9 nM, 146 ± 2.7 nM, 579 ± 4.16 nM, and 638 ± 5.09 nM, respectively (n= 35-65
cells) (Fig. 1C).
Neuroscience. Author manuscript; available in PMC 2019 May 01.
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PAF promotes Ca2+ influx in RBMVEC
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In Ca2+-free saline, or in the presence nifedipine (1μM), a L-type Ca2+ channels blocker the
Ca2+ response to PAF (1μM) was absent. Cells were pretreated with nifedipine 15 min
before PAF treatment. To verify the functionality of internal Ca2+ stores in RBMVEC, we
tested the Ca2+ response produced by ATP, an agonist known to generate inositol 1,4,5trisphosphate (IP3) and consequent Ca2+ release from endoplasmic reticulum Ca2+ stores. In
Ca2+-free saline, ATP (50 μM) induced a fast and transient increase in [Ca2+]i. Typical
examples of Ca2+ responses are shown in Fig. 1D and the comparison of the amplitude in
[Ca2+]i increase in each condition, is shown in Fig. 1E. In Ca2+-free saline, PAF (1 μM)
produced a minimal increase in [Ca2+]i by only 18 ± 2.23 nM (n = 45 cells), as compared to
an increase of [Ca2+]i by 579 ± 4.16 in Ca2+-containing saline. ATP (50 μM) increased Ca2+
by 248 ± 4.36 nM (n = 53 cells) in Ca2+-free saline. Pre-treatment with nifedipine (1μM, 15
min), similarly to Ca2+-free saline condition, inhibited the response to PAF; Δ [Ca2+]i = 11
± 1.97 nM (n= 43 cells), indicating that the PAF-induced increase in [Ca2+]i was produced
by Ca2+ influx.
PAF depolarized RBMVEC
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The effect of PAF on membrane potential was monitored in RBMVEC loaded with
DiBAC4(3). PAF (1μM) produced a depolarization with an average amplitude o f 8.27 ± 0.38
mV (n = 35 cells); in the presence of WEB2086, the effect of PAF was markedly
diminished; ΔV = 1.35 ± 0.24 mV. Pretreatment with nifedipine (1μM, 15 min), prevented
the PAF-induced depolarization (ΔV = 0.81 ± 0.21 mV), while L-NAME did not affect the
response to PAF (ΔV = 8.03 ± 0.41 mV). Averaged changes in membrane potential produced
by PAF in each condition are shown in Fig. 2A, and the comparison of the amplitude of
depolarization produced in each condition is shown in Fig. 2B.
PAF increases NO in RBMVEC
In cells loaded with DAF-FM, a NO-sensitive dye (Kojima et al, 1998), PAF (1 μM)
increased DAF-AM fluorescence ratio (Fig. 3). The response was abolished by WEB2086, a
PAF receptor antagonist, by L-NAME (100 μM), NO synthase inhibitor, or by nifedipine, a
L-type Ca2+ channel antagonist (Fig. 3A). PAF (1 μM) increased the fluorescence by about
30% (Δ DAF-FM = 0.32 ± 0.027). WEB2086, L-NAME and nifedipine reduced the response
to PAF to levels similar to control; ΔDAF-FM = 0.02 ± 0.011 in cells pretreated with
WEB2086, 0.016 ± 0.008 in cells pretreated with L-NAME, and 0.057 ± 0.011 in RBMVEC
treated with nifedipine (Fig. 3B).
PAF alters RBMVEC cytoskeleton and tight junctions
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We examined the distribution of ZO-1, a regulatory protein used as a marker for tight
junctions complex (Abbott et al., 2010, Molino et al., 2014) before and after treatment of
RBMVEC with PAF (1 μM). Treatment with PAF reduced the peripheral ZO-1 staining
indicative of disruption of tight junctions, and increased the formation of F-actin fibers,
suggesting cytoskeletal changes (Fig. 4A). Moreover, PAF promoted the intercellular gap
formation (Fig. 4A). Treatment of RBMVEC with WEB2086, L-NAME and nifedipine
while did not affect the ZO-1 and actin staining, but prevented the changes elicited by PAF.
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PAF disrupts endothelial barrier function
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ECIS experiments indicate that treatment of RBMVEC monolayers with PAF (1 μM)
produced a transitory decrease in the resistance part of impedance (Fig. 4B), indicative of
barrier function disruption. Blockade of PAF receptor with WEB2086 (5 μM) prevented the
response to PAF. The barrier-disruptive effect of histamine (10 μM) was used as a positive
control (Stolwijk et al., 2015, Stolwijk et al., 2016).
PAF did not affect RBMVEC viability
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Since earlier studies (Fang et al., 2011, Predescu et al., 2013) indicate that PAF at
concentration higher than 10-7 M had cytotoxic effects, we examined the effect of PAF on
RBMVEC viability, in our experimental conditions. Treatment with PAF (0.1 μM, 0.5 μM, 1
μM and 5 μM) for one hour, did not significantly affect the viability of RBMVEC, assessed
with MTT assay (Fig. 4C)
PAF increases BBB permeability
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In vivo studies examined the effect of systemic administration of PAF on the BBB
permeability by determining the concentration of sodium fluorescein and Evans Blue in the
rat brain. In control rats, the brain concentration of sodium fluorescein was 386 ± 47 ng/mg
(n = 6). Treatment with PAF (0.01 mg/kg) increased the brain concentration of sodium
fluorescein to 703 ± 84 ng/mg (n = 6). On the other hand, administration of WEB2086 (0.5
mg/kg), L-NAME (20 mg/kg), or nifedipine (0.3 mg/kg) 10 min before PAF reduced the
sodium fluorescein concentration in the brain to 426 ± 39 ng/mg, 402 ± 53 ng/mg and 447
± 61 ng/mg (n = 6), respectively (Fig. 5A). In experiments where BBB permeability was
assessed using Evans Blue, in control rats, the brain concentration of Evans Blue as 471 ± 54
ng/mg (n = 6). Treatment with PAF (0.01 mg/kg) increased the brain concentration of Evans
Blue to 1138 ± 74 ng/mg (n = 6). On the other hand, administration of WEB2086 (0.5 mg/
kg), L-NAME (20 mg/kg), or nifedipine (0.3 mg/kg) 10 min before PAF reduced the Evans
Blue concentration in the brain to 557 ± 61 ng/mg, 582 ± 64 ng/mg and 541 ± 67 ng/mg (n =
6), respectively (Fig. 5B).

Discussion
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Platelet-activating factor (PAF) is a phospholipid mediator involved in various
cardiovascular and CNS disorders (Prescott et al., 2000). While low basal PAF level was
detected in the brain (Kumar et al., 1988), increased brain PAF levels occurred after hypoxia
and reoxygenation injury (Deng et al., 2009), in response to convulsant stimuli (Kumar et
al., 1988) or in pathological conditions like multiple sclerosis (Callea et al., 1999) or HIV-1
infection (Gelbard et al., 1994). In addition to the synthesis in inflammatory cells, PAF can
also be produced by endothelial cells (Liu et al., 2016). In a porcine model, cultured brain
microvascular endothelial cells were reported to produce smaller amounts of PAF than aortic
endothelial cells (Satoh et al., 1995). As previous reports indicate that PAF produced an
increase in blood-brain barrier (BBB) permeability (Fang et al., 2011, Fang et al., 2014), we
examined the effect of PAF on rat brain endothelial cells (RBMVEC), an essential
component of the BBB.
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We found that in RBMVEC, PAF (0.1 - 5 μM) increased cytosolic Ca2+ concentration,
[Ca2+]i in a dose-dependent manner. Lower concentrations of PAF tested here (0.1 μM, 0.5
μM) mimic those found physiologically, while higher concentrations (>1 μM) were similar
to those found in inflammatory conditions (Reiner et al., 2016). The effect of PAF was
inhibited by the PAF receptor antagonist, WEB2086 (Ukena et al., 1988), furthering the
implication of PAF receptor activation as the impetus for the cytosolic Ca2+ increase
observed. Similarly, PAF increased [Ca2+]i in several other cell models like human
monocytic leukemic U-937 cells (Barzaghi et al., 1989), hippocampal neurons (Bito et al.,
1992), N1E-115 neuroblastoma cells (Diserbo et al., 1995), human and canine aortic
endothelial cells (Bkaily et al., 1993), bovine cerebral microvascular endothelial cells (Lin
and Rui, 1994), oviductal cells (Tiemann et al., 1996, Tiemann et al., 1999) and rat brain
microvessel endothelial cells (Deng et al., 2009). Earlier studies indicate that PAF produced
phosphoinositide hydrolysis, synthesis of inositol phosphates and release of Ca2+ from
endoplasmic reticulum stores, suggestive of Gq-protein signaling (Shukla, 1992, Kamata et
al., 1993b). PAF receptor has been reported to signal also via Go and Gi proteins (Alexander
et al., 2015).
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In RBMVEC, Ca2+ influx and not Ca2+ release from internal stores was responsible for the
increase in [Ca2+]i produced by PAF. Significant differences were reported in different
cellular models between Ca2+ sources mobilized by PAF. While release of Ca2+ from
internal stores was responsible for part of the Ca2+ increase, Ca2+ influx was considered the
predominant mechanism elicited by PAF in platelets (Hallam et al., 1984), and U-397 cells
(Barzaghi et al., 1989). In human airway epithelial cells (Stoll et al., 1994), or N1E-115
neuroblastoma cells (Diserbo et al., 1995) PAF produced both a Ca2+ release from internal
stores and Ca2+ influx. On the other hand, in NG108 cells (Kornecki and Ehrlich, 1988),
human platelets (Avdonin et al., 1991), bovine oviductal cells (Tiemann et al., 1996,
Tiemann et al., 1999) similarly to RBMVEC, PAF produced Ca2+ influx. However, in
oviductal cells, PAF-induced Ca2+ influx was not affected by verapamil (Tiemann et al.,
1996), but blocked by flufenamic acid or TMB-8 (Tiemann et al., 1999), indicating the
involvement of non-selective cationic channels. In bovine cerebral microvascular endothelial
cells, PAF increased [Ca2+]i via phospholipase C-dependent mechanism, while blockade of
Ca2+ influx with diltiazem or verapamil did not affect the response (Lin and Rui, 1994). On
the other hand, in RBMVEC, PAF produced Ca2+ influx was sensitive to nifedipine,
indicating the participation of L-type voltage-gated Ca2+ channels, and supporting different
Ca2+ influx mechanisms between different cell types and/or species differences.
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An increase in [Ca2+]i may lead to an increase in NO production consequent to the Ca2+dependent activation of endothelial NO synthase (eNOS) (Fleming et al., 1997). In
RBMVEC, PAF produced an increase in NO levels; the effect was sensitive to the PAF
receptor antagonist and NO synthase inhibitor. In addition, the increase in NO produced by
PAF was abolished by a L-type Ca2+ channel blocker, indicating that the increase in [Ca2+]i
by Ca2+ influx was a determinant of NO production. PAF has been reported to increase NO
production via eNOS phosphorylation in other endothelial cells such as mouse pulmonary
artery and lung microvascular endothelial cells (Predescu et al., 2013) and bovine coronary
postcapillary venular endothelial cells (Sanchez et al., 2008) and produced subsequent
increase in permeability. While these earlier studies examined the structural and functional
Neuroscience. Author manuscript; available in PMC 2019 May 01.
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relationship of PAF receptor and eNOS at the plasma membrane microdomains, we
examined the PAF-induced NO production in the context of the effect of PAF on [Ca2+]i
concentration, membrane potential and their significance on endothelial permeability in vitro
and in vivo.
We also identified that PAF depolarized RBMVEC loaded with a slow response voltagesensitive fluorescent dye, DiBAC4(3); the response was significantly diminished by
antagonism of PAF receptor or by inhibition of Ca2+ influx. Similarly, earlier studies
reported that PAF depolarized human or rabbit neutrophils (Naccache et al., 1986, Lerner et
al., 1988) human platelets (Avdonin et al., 1991), bovine oviductal cells (Tiemann et al.,
1999) or rat stomach fundus (Kamata et al., 1993a). Depolarization of vascular endothelial
cells was associated with NO production and increased cellular stiffness via reorganization
of cortical actin cytoskeleton (Callies et al., 2011).
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Brain microvascular endothelial cells are characterized by low paracellular permeability due
to the presence of tight junctions between adjacent cells (Abbott et al., 2010). Tight
junctional complex comprises of occludin, claudins and regulatory zonula occludens
(Coeffier et al.) proteins (Aijaz et al., 2006). ZO-1, an intracellular regulatory protein, links
the tight junctions molecules claudin and occludin to intracellular actin and the cytoskeleton
and is widely used as a marker for tight junctions (Hawkins and Davis, 2005, Abbott et al.,
2010). Our results indicate that, in RBMVEC, PAF reduced ZO-1 staining. Similarly, PAF
reduced ZO-1 expression in human umbilical vein endothelial cells (HUVEC) (Jeewandara
et al., 2015). A decrease in ZO-1 expression or immunoreactivity has been associated with
an increase in BBB permeability (Abbruscato et al., 2002, Hawkins and Davis, 2005,
Reinhold and Rittner, 2017). PAF also produced an increase in F-actin staining and induced
intercellular gaps. Similar changes were produced in microvascular endothelial cells by
other agonists such as bradykinin (Liu et al., 2008), thrombin (Stolwijk et al., 2016, Brailoiu
et al., 2017) and glutamate (Andras et al., 2007) or by hypoxia (Brown and Davis, 2005). In
human dermal microvascular endothelial cells (HDMEC), actin fibers were found to
redistribute to the cytosol 2-5 min after thrombin stimulation and toward the cell membrane
after 30 min (Stolwijk et al., 2016). PAF increased actin cytoskeleton in rabbit neutrophils
(Naccache et al., 1986) and increased contractility of rat stomach fundus (Kamata et al.,
1993a).
In endothelial cells, an increase in [Ca2+]i modulates junctional and cytoskeletal proteins,
promotes phosphorylation of myosin light chain kinase, actin-myosin interaction and
increases paracellular permeability (De Bock et al., 2013). Our ECIS experiments indicate
that PAF decreased the electrical resistance, indicative of an increase in paracellular current
flow. Similarly, PAF decreased electrical resistance in mouse pulmonary artery and lung
microvascular endothelial cells (Predescu et al., 2013). A previous report indicates that the
decrease in the trans-endothelial resistance (TEER) of HUVECs produced by PAF from the
serum of patients with dengue fever played a critical role in the increased vascular
permeability (Jeewandara et al., 2015). PAF was involved in the increase vascular
permeability in experimental cerebral malaria (Lacerda-Queiroz et al, 2012) and anaphylaxis
(Vadas et al, 2013). Other GPCR agonists, such as thrombin or histamine, were shown to
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produce endothelial barrier dysfunction subsequent to morphological changes,
rearrangement of actin cytoskeleton and junctional proteins (Stolwijk et al, 2016).

Author Manuscript

To further determine the significance of our in vitro studies, we investigated the in vivo
effects of PAF on BBB permeability in rat, assessed with sodium fluorescein and Evans
Blue. Earlier in vivo studies reported the PAF (1 μM, 1 h) induced transient and reversible
BBB opening (Fang et al, 2014), while longer exposure to PAF (1 μM, 24h) increased
permeability of RBMEC by upregulating intercellular adhesion molecule-1 (ICAM-1) and
had cytotoxic effect (Fang et al, 2011). Our in vivo studies indicate that PAF increased the
BBB permeability; the effect was sensitive to antagonism of PAF receptor. This finding is in
agreement with a relatively recent study reporting a preserved integrity of blood-brain
barrier in mice lacking the PAF receptor, PAFR(-/-) (Toscano et al, 2016). Blockade of Ca2+
influx or of NO formation also prevented the increase in BBB permeability produced by
PAF, indicating a central role of the increase in [Ca2+]i and subsequent NO formation in this
effect. Taken together, our studies identify multiple mechanisms by which PAF modulates
the function of the brain microvascular endothelial cells and ultimately increases the
permeability of the blood-brain barrier, relevant for the cerebrovascular inflammatory
disorders.
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blood-brain barrier

[Ca2+]i

cytosolic Ca2+ concentration

ECIS

Electric Cell-Substrate Impedance Sensing

HBSS

Hanks' Balanced Salt Solution

NO

nitric oxide

PBS

phosphate buffer saline

RBMVEC rat brain microvascular endothelial cells
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Highlights
•

We examined the effect of PAF on rat brain microvascular endothelial cells
(RBMVEC) using in vitro and in vivo assays

•

In addition to increasing cytosolic Ca2+ and NO production, we show for the
first time that PAF depolarized RBMVEC

•

PAF-induced changes in F-actin and tight junctions converged in a reduced
electrical resistance and increased permeability

•

Our results reveal multiple mechanisms by which PAF increases BBB
permeability, relevant to CNS inflammatory disorders
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Figure 1. PAF increases cytosolic Ca2+ concentration, [Ca2+]i, by promoting Ca2+ influx in
RBMVEC
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A , Examples of fura-2 AM fluorescence ratio (F340/F380) in RBMVEC before (basal) and
after treatment with PAF (1 μM). Cold colors represent low ratios and hot colors represent
high ratio (scale 0-2). B, Representative examples (average ± SEM) of [Ca2+]i increases
produced by PAF (1 μM) and PAF (1 μM) in the presence of PAF receptor antagonist
WEB2086 (5 μM). PAF produced a fast and transient increase in [Ca2+]i; the response was
inhibited by WEB2086. C, Comparison of the amplitude of [Ca2+]i increase produced by
each concentration of PAF tested (0.1 μM, 0.5 μM, 1 μM and 5μM) and by PAF (1 μM) in
cells pretreated with WEB2086 (5 μM). P < 0.05 as compared to the response to the other
concentrations of PAF tested (*), or to the response produced by PAF 1 μM (#). D, In Ca2+free saline, PAF (1 μM) did not elicit an increase in [Ca2+]i., while ATP (50 μM) increased
[Ca2+]i, indicating the integrity of internal Ca2+ stores. Pretreatment with the L-type Ca2+
channels blocker, nifedipine (1 μM), prevented the increase in [Ca2+]i produced by PAF. E,
Comparison of the amplitude of [Ca2+]i responses elicited in Ca2+-free saline by PAF (1
μM) and ATP (50 μM) (top) and in Ca2+-containing saline (bottom) by or PAF (1 μM) alone
or by PAF (1 μM) in cells pretreated with nifedipine (1 μM) (bottom). P < 0.05 as compared
to ATP-induced response in Ca2+-free (*) or to PAF-induced response in Ca2+-containing
saline (#).
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Figure 2. PAF elicits RBMVEC depolarization
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A, Averaged changes in membrane potential ± SEM in response to PAF (1 μM), PAF in the
presence of the PAF antagonist, WEB2086 (5 μM), nifedipine (Nif, 1 μM) or L-NAME (100
μM). Treatment of RBMVEC with PAF (1 μM) induced a depolarization that was prevented
by WEB2086 (5 μM), and nifedipine (1 μM) but it was not affected by L-NAME. B,
Comparison of the average amplitude of the depolarization produced by PAF alone or in the
presence of WEB2086, nifedipine or L-NAME. *P < 0.05 as compared to the effect of PAF
in presence of PAF antagonist, WEB2086, or nifedipine. NS, P > 0.05 between treatment
groups.
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Figure 3. PAF increases NO production in RBMVEC
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A , Averaged DAF-FM fluorescence ratios ± S.E.M. in cells treated with PAF (1 μM) (top
left trace), PAF (1 μM) in the presence of WEB2086 (top right trace), PAF (1 μM) in the
presence of L-NAME (bottom left trace) or PAF (1 μM) in the presence of nifedipine
(bottom right trace). B, Comparison of ΔDAF-FM in cells treated with PAF (1 μM) in the
absence and presence of WEB2086, L-NAME, or nifedipine (Nif). (*) P < 0.05 as compared
to response to PAF alone. NS, P > 0.05 as compared to the other treatment groups.
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Figure 4. PAF produced cytoskeletal and tight junction changes and barrier dysfunction in
RBMVEC
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A, Distribution of ZO-1 (green), a component of tight junctions and F-actin (red), a
component of cytoskeleton, in control RBMVEC, and cells treated with PAF (1 μM) in the
absence and presence of PAF receptor antagonist. WEB2086. WEB2086, L-NAME and
nifedipine (Nif) did not have any effect on ZO-1 or actin staining, but prevented the effect of
PAF. Nuclei are stained with DAPI (blue). Treatment with PAF produced a reduction in
ZO-1 staining, increased actin fibers, and intercellular gaps (arrows). B, Examples of
changes in normalized electrical resistance of confluent RBMEC monolayer after histamine
(10 μM), PAF (1 μM), PAF + WEB (5 μM). PAF, similarly to histamine, decreased electrical
resistance; the response to PAF was abolished by WEB2086. C. PAF (0.1 μM – 5 μM) did
not significantly affect RBMVEC viability assessed with MTT assay.
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Figure 5. PAF produced an increase in the permeability of the blood-brain barrier (BBB) in vivo
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A, PAF (0.01 mg/kg) increased the permeability of the BBB assessed using the sodium
fluorescein assay. B, PAF (0.01 mg/kg) increased the BBB permeability assessed using the
Evans Blue method *P < 0.05 as compared to control, or to the effect of PAF in presence of
PAF antagonist, WEB2086, L-NAME or nifedipine. NS, P > 0.05 between treatment groups.
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